Home > Boards > US Listed > Biotechs >

ImmunoTech (AIM)

AIM RSS Feed
Add AIM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Taurus69
Search This Board: 
Last Post: 11/17/2020 10:58:45 PM - Followers: 67 - Board type: Free - Posts Today: 0




 

About AIM ImmunoTech

 
 

AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers,
as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids
and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.

AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3).
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment)
or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.

We operate a 30,000 sq. ft. facility in New Brunswick, NJ with the objective of producing Ampligen® and Alferon®.
We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and
expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.

https://aimimmuno.com/blog/

CEO Roadshow Interviews Hemispherx Thomas K. Equels

April 4th, 2019

CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]

IM ImmunoTech Reaches Deal with Japan’s National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus

Introducing You to the First Ampligen Quarterly Update

March 25th, 2019

Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the [...]

March 9th, 2020

AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus
On March 9 th we announced that Japan’s National Institute of Infectious [...]

https://aimimmuno.com/all-articles/
 

AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19

AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19 SNNLive caught up with Thomas Equels, CEO AIM ImmunoTech Inc. Watch the full video here. [...]

AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers

AIM ImmunoTech Announces the National Cancer Institute's Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers We recently announced [...]

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic We recently announced the AIM ImmunoTech team is working [...]

 

AIM ImmunoTech Reaches Deal with Japan’s National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus

AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus On March 9 th we announced that Japan’s National Institute of Infectious [...]

 


https://aimimmuno.com/
 AIM ImmunoTech is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders
Investor Relations
AIM ImmunoTech is committed to providing up to date information to shareholders, analysts, and potential investors. Get the latest from our blog.

Products
AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a developmental first-in-class drug of large macromolecular RNA molecules.
AIM IMMUNOTECH INC.

Product Candidates Overview

Ampligen®

Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® has in the clinic demonstrated the potential for standalone efficacy in a number of solid tumors.
We have also seen success in increasing survival rates and efficacy in the treatment of animal tumors when
Ampligen® is used in combination with checkpoint blockade therapies.
This success in the field of immuno-oncology has guided our focus toward the potential use of Ampligen®
as a combinational therapy for the treatment of a variety of solid tumor types.
There are currently multiple Ampligen® clinical trials — both underway and planned — at major cancer research centers around the country.
Ampligen ® is also being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP)
approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.

Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). AIM ImmunoTech
is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the U.S.
In August 2016, we received approval of our NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)
for commercial sale of Ampligen® in the Argentine Republic for the treatment of severe CFS. With regulatory approval in Argentina,
Ampligen® is the world’s only approved therapeutic for ME/CFS.
We continue to pursue our Ampligen New Drug Application, or NDA, for the treatment of CFS with the Food and Drug Administration, or FDA.

Alferon N Injection®

Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory
(resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
Certain types of human papilloma viruses cause GW. AIM ImmunoTech also has approval from ANMAT for the treatment of
refractory patients that failed or were intolerant to treatment with recombinant interferon in Argentina.
We have developed and, with proper funding, will be seeking FDA Pre-Approval Inspection of a high-volume, high-efficiency,
upgraded manufacturing process to allow for the commercial viability of Alferon®.

Pipeline
https://aimimmuno.com/pipeline/




Partnering
https://aimimmuno.com/partnering/

AIM ImmunoTech

Is committed to advancing our technology platforms and product candidates. In order to pursue this goal, AIM ImmunoTech is highly interested in collaborative opportunities including product out-licensing, co-research, co-development, co-promotion, and co-marketing with research institutes, pharmaceutical companies, and biotech companies domestically and internationally.

Ampligen

  • Cancer
    Vaccine Adjuvant
    Broad Spectrum Antiviral
    Traumatic Injury / Burns Immunodeficiency

Alferon

  • Broad Spectrum Antiviral
    Genital Warts
    Anti-Cancer
    Argentina Approval
    Intralesional treatment of external genital warts refractory or recurring
    Treatment patients who initially responded to recombinant interferon alpha, including pegylated interferon alfa, but later treatment failed due to the presence of neutralizing antibodies.

 

Contact Us

Please direct your inquiries regarding business development and licensing opportunities to: info@AIMImmunoTech.com

 


 

2117 SW Highway 484

Ocala, FL 34473

www.hemispherx.net(352) 448-7797


https://www.otcmarkets.com/stock/AIM/disclosure

https://www.otcmarkets.com/stock/AIM/news

https://www.otcmarkets.com/stock/AIM/security
AIM SECURITY DETAILS

Share Structure

Market Cap Market Cap   72,966,225
06/25/2020
 
Authorized Shares
Not Available
 
Outstanding Shares   29,186,490
05/10/2020


https://www.otcmarkets.com/stock/AIM/profile

https://www.otcmarkets.com/stock/AIM/quote

https://www.otcmarkets.com/stock/AIM/overview

https://finviz.com/quote.ashx?t=aim
Book/sh 1.96
Cash/sh 0.84
 
 
Debt/Eq 0.19
 
LT Debt/Eq 0.18
Shs Outstand 32.62M
 
Shs Float 28.77M
Short Float 5.87%







*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.






 
AIM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AIM News: AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as... 11/25/2020 06:45:00 AM
AIM News: Current Report Filing (8-k) 11/23/2020 09:06:12 AM
AIM News: AIM ImmunoTech Provides Third Quarter 2020 Business Update 11/13/2020 07:30:00 AM
AIM News: Quarterly Report (10-q) 11/12/2020 04:47:31 PM
AIM News: AIM ImmunoTech Announces PLOS ONE’s Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen’s... 11/02/2020 09:00:00 AM
PostSubject
#1901  Sticky Note $AIM this is good AIM ImmunoTech Added to mick 06/30/20 10:09:08 AM
#1984   $aim $1.96 v -0.05 (-2.49%) Taurus69 11/17/20 10:58:45 PM
#1983   This is a very old company and the Richard2 11/13/20 08:41:23 PM
#1982   $aim $1.92 v -0.12 (-5.88%) Taurus69 11/09/20 06:18:14 PM
#1981   I am in very early stages of taking bwolfy2002 11/05/20 10:21:35 AM
#1980   $aim $2.14 ^ 0.06 (2.88%) Taurus69 10/25/20 06:52:37 PM
#1979   AIM ImmunoTech Inc (AIM) mick 10/25/20 04:46:31 PM
#1978   $aim $2.21 ^ 0.1 (4.74%) Taurus69 10/03/20 01:25:59 PM
#1977   $aim $2.14 v -0.06 (-2.73%) Taurus69 09/29/20 08:50:59 PM
#1976   AIM ImmunoTech Inc (AIM) mick 09/25/20 07:56:05 PM
#1975   LOCK YOUR SHARES TO $8.81 - 9.00 BOOMAGE!!! ALL-IN888 09/25/20 12:11:39 PM
#1974   * * $AIM Video Chart 09-22-2020 * * ClayTrader 09/22/20 04:50:33 PM
#1973   I have to agree. No position. Femto99 09/22/20 02:15:30 PM
#1972   Lock your Shares now to 6.50 PT $$$$ ALL-IN888 09/22/20 12:18:17 PM
#1971   BREAKING NEWS: $AIM AIM ImmunoTech Receives Statistically Significant whytestocks 09/22/20 11:30:29 AM
#1970   I'll pass on this one. Pedro2004 09/22/20 09:45:26 AM
#1969   AIM used to be HEB. Pedro2004 09/22/20 09:22:07 AM
#1968   Great call. Heavy share dumping this morning. Pedro2004 09/22/20 08:41:46 AM
#1967   News caught my eye. But it's trading like Pedro2004 09/22/20 08:27:33 AM
#1966   Good Luck BEIJING BILL 09/22/20 08:21:51 AM
#1965   Bonzaiiiiii folow the $$$$ BEIJING BILL 09/22/20 08:14:51 AM
#1964   went short 2.77. gap needs filled. cspratt15139 09/22/20 07:40:31 AM
#1963   AIM LOOKING GOOD TODAY. AIM DRUG GROUP STUDY otcmoneydoubler 09/22/20 07:33:22 AM
#1962   Covid vill be heating up ahain. BEIJING BILL 09/14/20 09:11:19 AM
#1961   Folow the mony BEIJING BILL 09/09/20 09:01:46 AM
#1960   AIM ImmunoTech Inc (AIM) mick 09/05/20 03:16:03 PM
#1959   * * $AIM Video Chart 08-27-2020 * * ClayTrader 08/27/20 05:56:28 PM
#1958   News; $AIM AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious whytestocks 08/27/20 04:16:14 PM
#1957   $aim $2.12 v -0.05 (-2.30%) Taurus69 08/26/20 10:35:09 PM
#1956   Awesome ! Let’s get active , wouldn’t want clotter2 08/23/20 09:14:02 AM
#1955   Nice bounce this morning ...AIM GREGG THE GREEK 08/21/20 11:39:16 AM
#1954   Been trading this one at higher levels. GREGG THE GREEK 08/20/20 11:57:10 AM
#1953   AIM looking like bottom is in doebop 08/18/20 12:13:54 PM
#1952   AIM ImmunoTech Inc (AIM) mick 08/15/20 11:49:13 PM
#1951   http://archive.fast-edgar.com/20200803/AF2YM22CZC2RS9PD222B2ZY2G3GDZZ22Z222/ [SMART MONEY] 08/03/20 07:11:16 AM
#1950   $AIM AIM ImmunoTech Inc (AIM) mick 08/01/20 12:11:14 PM
#1949   $aim $2.92 ^ 0.15 (5.42%) Taurus69 07/31/20 10:08:30 PM
#1948   $AIM, anything wit covid-19 in it is serious mick 07/31/20 03:39:21 PM
#1947   $AIM, IT IS INTERESTING PRODUCT mick 07/31/20 03:38:41 PM
#1946   An update from this company could send this parabolic. INTL 07/31/20 11:26:58 AM
#1945   Loading before Mondays presentation. INTL 07/31/20 11:16:32 AM
#1944   Broke 3 BEIJING BILL 07/31/20 11:02:18 AM
#1943   I my eyes here now mick BEIJING BILL 07/31/20 10:52:10 AM
#1942   AIM ImmunoTech Inc (AIM) mick 07/25/20 01:43:45 PM
#1941   News: $AIM Ergomed H1 2020 Trading Update whytestocks 07/21/20 07:30:47 AM
#1940   * * $AIM Video Chart 07-20-2020 * * ClayTrader 07/20/20 04:04:06 PM
#1939   I was referring to whytestocks postings... mantisforce 07/20/20 02:40:51 PM
#1938   wrong pump and dump company lowfloatwayne 07/20/20 02:13:38 PM
#1937   Moderators is this Spamming the board...News: $AIM Marimaca mantisforce 07/20/20 01:52:39 PM
#1936   News: $AIM Marimaca Copper: Appointment of Company President whytestocks 07/20/20 12:45:27 PM
#1935   AIM earnings are Aug. 10th... streetsmartstocks 07/20/20 12:44:00 PM
PostSubject
Consent Preferences